Abstract
Botulinum neurotoxin (BoNT) is the most toxic protein known to science. It is also the active ingredient in
®
pharmaceutical products like Botox (Allergan), which have proven safe and effective for multiple neuromuscular
indications. All current BoNT products are manufactured from Clostridium botulinum cultures and have similar
safety characteristics, which include limitations on dosing and a black box warning in labeling. Because of its
inherent toxicity and narrow therapeutic window, optimal clinical outcomes are difficult to achieve in indications
involving large muscle groups, such as cervical dystonia, post-stroke spasticity and pediatric cerebral palsy.
Though improved muscle tone can clearly be achieved, clinicians tend to dose on the side of caution, and overall
clinical outcomes leave significant room for improvement. We here propose building on data generated with a
previous candidate for a “safer BoNT” pharmaceutical (SBIR Phase 1 1R41NS086115-01A1) which found that
specific amino acid substitutions to BoNT/A1 can produce a recombinant BoNT/A1 with an improved safety
margin compared to wt BoNT/A1, (US 8,865,186). The initial lead candidate designed and tested, Cyto-012, had
an improved safety margin, but its absolute potency was such that doses required for efficacy were also
immunogenic. Here, we propose testing a new recombinant BoNT/A1 derivative termed Cyto-014, designed to
have potency and immunogenicity similar to wt BoNT/A1, while retaining the desired improvement in safety
suggested by our Preliminary Studies. This proposal is intended to compare the dose-response behavior, safety
margin and maximum tolerated dose of Cyto-014 relative to wt BoNT/A1 in appropriately powered studies, and
to evaluate its immunogenicity and effectiveness for repeat treatment. Successful completion of the proposed
studies will support a Phase II study to focus on pre-clinical development activities aimed at filing an IND.
